Dexcom

DXCM on Nasdaq. Dexcom sells glucose monitoring systems to people with diabetes and their doctors. Market value $31.1bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Good business, but not cheap right now

See cheaper Health care stocks on the list

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
3.7%fair

For every $100 of what the whole company costs, it produced $3.67 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 79 of 100. Price score: 55 of 100. Our list needs 70 on quality and 60 on price.

$80.19 a share, 41% above its 1-year low

Over the past year the price has ranged from $56.72 to $92.59.

Pays no dividend

Price from Thursday’s close (19 November).

Five years of cash, in billions

0.1
0.3
0.5
0.6
1.1
1.1
2021202220232024202512 monthsto Sep '26
Revenue
$2.4bn$2.9bn$3.6bn$4.0bn$4.7bn
Operating margin
10.9%13.4%16.5%14.9%19.6%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.39bn0.39bn0.39bn0.39bn0.37bn

Health checks

  • Free cash flow positive5 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)7 of 8 checks we could run
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsStrong, 19.3% a year
  • Buying back its own sharesYes, 3% fewer since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $1.3 billion last quarter, up 11% on a year ago.
  • Profit: $275 million, down 3% on a year ago.
  • It keeps 24 cents of each $1 of sales as operating profit, up from 17 cents a year earlier.
  • Spare cash over the past 12 months: $1.1 billion, about the same as a year earlier.
  • 6% fewer shares than a year ago. Each share owns a bit more of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$1.1bn
March 2025$1.0bn
June 2025$1.2bn
September 2025$1.2bn
December 2025$1.3bn
March 2026$1.2bn
June 2026$1.3bn
September 2026$1.3bn
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024$152m
March 2025$105m
June 2025$180m
September 2025$284m
December 2025$267m
March 2026$200m
June 2026$249m
September 2026$275m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
11 February 2027
Last annual report (10-K)
12 February 2026
Next quarterly (estimated, 10-Q)
28 January 2027

Who owns it

2 long-term investors we follow own it, down from 3 last quarter. 971 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

4 investors own more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 8 sold $13m, $13m of it under preset trading plans.

  • Brown Michael Jon
    EVP Chief Legal Compliance Off
    Sold
    under a preset trading plan
    Date
    16 November 2026
    Shares
    1,700
    Price
    $83.46
    Value
    $141,882
  • Stern Sadie
    EVP Chief People & Culture Off
    Sold
    under a preset trading plan
    Date
    27 October 2026
    Shares
    2,565
    Price
    $78.62
    Value
    $201,660
  • Brown Michael Jon
    EVP Chief Legal Compliance Off
    Sold
    under a preset trading plan
    Date
    15 October 2026
    Shares
    1,700
    Price
    $85.48
    Value
    $145,316
  • Stern Sadie
    EVP Chief People & Culture Off
    Sold
    under a preset trading plan
    Date
    28 September 2026
    Shares
    2,565
    Price
    $86.15
    Value
    $220,975
  • AUGUSTINOS NICHOLAS
    Director
    Sold
    under a preset trading plan
    Date
    15 September 2026
    Shares
    6,539
    Price
    $84.04
    Value
    $549,538
  • Brown Michael Jon
    EVP Chief Legal Compliance Off
    Sold
    under a preset trading plan
    Date
    15 September 2026
    Shares
    1,700
    Price
    $84.04
    Value
    $142,868
  • AUGUSTINOS NICHOLAS
    Director
    Sold
    under a preset trading plan
    Date
    14 September 2026
    Shares
    1,550
    Price
    $84.02
    Value
    $130,231
  • Sylvain Jereme M
    EVP, Chief Financal Officer
    Sold
    under a preset trading plan
    Date
    10 September 2026
    Shares
    3,638
    Price
    $83.27
    Value
    $302,936
  • Stern Sadie
    EVP Chief People & Culture Off
    Sold
    under a preset trading plan
    Date
    27 August 2026
    Shares
    2,565
    Price
    $88.37
    Value
    $226,669
  • SAYER KEVIN R
    Executive Chair, Director
    Sold
    under a preset trading plan
    Date
    20 August 2026
    Shares
    26,756
    Price
    $90.01
    Value
    $2m

From Form 4 filings: insiders must report trades in their own company's shares within two days.

How the boss is paid

Kevin Sayer was paid $16.3 million in 2025, about 278 times the typical employee’s pay.

  • The yearly bonus pays for per-share results:

    No — it uses sales and profit targets. See it in the filing

  • The long-term stock award pays for per-share results:

    Yes — it uses shareholder return. See it in the filing

Why it matters: new shares can grow total profit while each share earns less. Per-share goals pay the boss only when your slice grows.

From the proxy statement (the company’s yearly voting pack) filed 15 April 2026. Picked out automatically from the company’s own filing. Evidence, not our verdict.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the serious warning signs we check for were found. 1 thing worth knowing.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Feb 2026, plus the 10-Q filed 29 Oct 2026 and 9 later 8-Ks.

  • Changed auditor

    Worth knowing

    The company changed its auditor (the firm that checks its books) in the last two years.

    “On March 21, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of DexCom, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.”

    From an 8-K filed 25 March 2025: Change of auditor. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

What changed in the risks this year

Companies must list what could hurt them each year. These are the parts that changed since last year’s report.

  • Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.

    Could happen
    Moreover, we are subject to various operational, compliance, and reputational risks associated with our adoption and utilization of AI technologies, including inaccurate or unpredictable outputs, such as errors or hallucinations, that may impair decision‑making, disrupt operations, or expose sensitive information. Integrating AI into our systems may also expand our cybersecurity attack surface, increasing exposure to data breaches, loss of intellectual property, or inadvertent disclosure of confidential data. Although we have taken steps intended to mitigate risks related to our use of AI, there can be no assurance that our use of AI will yield the anticipated benefits or that we will be able to effectively mitigate the associated risks. Externally, the rapid adoption of AI by competitors and malicious actors heightens risks as threat actors leverage AI to execute more sophisticated cyberattacks and social‑engineering campaigns, while competitor use of AI may accelerate innovation cycles and intensify competitive pressures. Any of these events could have a material adverse effect on our business, financial condition and results of operations.
    Read more
  • If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.

    Could happen
    Notably, the new bidding system for Medicare competitive bidding will contain a “country of origin” question to obtain information about where products are manufactured. It is unclear how CMS intends to use this information and what impact this could have, if any, on our offshore manufacturing activities.
    Read more
  • Our products may not achieve or maintain market acceptance.

    Could happen
    • our G6 and G7 systems prompt the user to replace the sensor no later than the tenth day, and our G7 15 Day prompts the user to replace the sensor no later than the fifteenth day, which might make it expensive for users;
  • If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.

    Could happen
    In the United States and other countries, government and private sector access to health care products continues to be a subject of focus, and efforts to reduce health care costs are being made by third-party payors. Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of the G6, G7, G-7 15 Day, Dexcom One, and Dexcom ONE+. We expect that these continuing cost reduction and containment measures could result in lower prices for these products and lower reimbursement rates, as well as could lead to patients being unable to obtain approval for coverage or payment from these third-party payors resulting in costs being shifted to patients for these products. Additionally, we may experience pricing pressure if our products are increasingly subject to competitive bidding processes, which include substantial costs and managerial time to prepare bids and proposals for contracts that may not be awarded to us or may be split among competitors. For example, in June 2025, the Centers for Medicare & Medicaid Services published a proposed rule that would subject continuous glucose monitors to the competitive bidding process, which could negatively impact our reimbursement and result in price decreases. In late 2025, CMS extended the DMEPOS competitive bidding program to include our CGMs and receivers, with contracting beginning in 2027 and payment changes taking effect in 2028. Under the program, DMEPOS suppliers compete to become Medicare contract suppliers by submitting bids to furnish certain items in CBAs. CMS anticipates that ten (10) contracts will be awarded for CGMs. However, while the competitive bidding program previously used CBAs for contract awards, CMS determined that for CGMs and certain other DME, a RID CBA was more appropriate. It remains to be seen whether CGMs will be covered under a single, nationwide RID CBA or whether regional RID CBAs will be established. In any event, the bid process is expected to result in lower Medicare reimbursement for CGM systems, particularly because CMS is changing the pricing under the RID CBA by setting a single payment amount for covered items at the 75 th percentile of the winning bids, rather than using the maximum winning bid. Further, CMS has reclassified CGMs and insulin infusion pumps to items that require frequent and substantial servicing and will phase in monthly rental payments for these items. CMS will bundle the rental amount for the receiver device with payment for the supplies and accessories in the new payment amount. The bid limit will be monthly fee schedule amounts for the supplies plus the average purchase fee schedule amounts for the CGM receiver device divided by 60 (intended to capture the 5-year useful life of the device.) As a result, we expect that Medicare reimbursement for our CGM systems will decrease beginning in 2028. CMS is required by law to recompete these contracts at least once every three years and to roll out the competitive bidding process nationally or adjust prices in non-competitive bidding areas to match competitive bidding prices. The implementation of the competitive bidding program is expected to result in reduced Medicare payment for CGMs in both competitive bidding areas and non-competitive bidding areas. Additionally, the new bidding system will contain a “country of origin” question to obtain information on where products are manufactured; however, it is unclear how CMS intends to use this information. Given that we maintain offshore manufacturing facilities, country of origin reporting could have an impact on our business. Competitive bidding could negatively impact our reimbursement and result in price decreases. To the extent these cost containment efforts are not offset by greater patient access to our products, our revenue may be reduced and our business may be harmed.
    Read more
  • We cannot guarantee that the 2025 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.

    Could happen
    In April 2025, our Board of Directors authorized and approved a share repurchase program of up to $750.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2026, or the 2025 Share Repurchase Program. Repurchases of our common stock under the 2025 Share Repurchase Program may be made from time to time in the open market, in privately negotiated transactions or by other methods, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, at our discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Exchange Act and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at our discretion. The 2025 Share Repurchase Program does not obligate us to repurchase any dollar amount or number of shares of our common stock, and the program may be extended, modified, suspended, or discontinued at any time.
    Read more

Read it in the annual report

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

The company just reported its latest figures. The deep dive shows what they mean for the price you pay.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.